(Q37801555)

23 August 2017

Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis (English)

1 reference

23 August 2017

1 reference

C B Confavreux

1

1 reference

PubMed ID

20959960

23 August 2017

R D Chapurlat

series ordinal

2

1 reference

PubMed ID

20959960

23 August 2017

language of work or name

English

0 references

publication date

20 October 2010

1 reference

Osteoporosis International

23 August 2017

1 reference

23 August 2017

22

1 reference

23 August 2017

4

1 reference

23 August 2017

1023-1036

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-010-1462-4

23 August 2017

0 references

cites work

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image atlas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Elucidation of the relationship between synovitis and bone damage: A randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Magnetic resonance imaging and miniarthroscopy of metacarpophalangeal joints: sensitive detection of morphologic changes in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Measurement of hand bone mineral content by dual energy x-ray absorptiometry: development of the method, and its application in normal volunteers and in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Bone mineral density of the hand in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Hand bone densitometry: a more sensitive standard for the assessment of early bone damage in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Detailed analyses of periarticular osteoporosis in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

A comparative review of the different techniques to assess hand bone damage in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Urinary cross-linked N-telopeptides of type I collagen levels in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Loss of trabecular bone mineral density in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Maintenance Infliximab Treatment Is Associated with Improved Bone Mineral Density in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Diagnosis of osteoporosis and assessment of fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

FRAX and the assessment of fracture probability in men and women from the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Bone turnover in non-steroid treated rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Transcription factors in bone: developmental and pathological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Osteoclasts are essential for TNF-alpha-mediated joint destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Interleukin-17 and type 17 helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Interleukin-6 as a key player in systemic inflammation and joint destruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Interleukin 6: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Endocrine regulation of energy metabolism by the skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

The role of interleukin-1 in bone resorption in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Interleukin-1 alpha activates an NF-kappaB-like factor in osteoclast-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Radiographic data from recent randomized controlled trials in rheumatoid arthritis: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Cytokines and bone loss in a 5-year longitudinal study--hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Allelic variation at the interleukin-1 receptor antagonist gene is associated with early postmenopausal bone loss at the spine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1--receptor antagonist gene but not with polymorphisms in the interleukin-1beta gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Nonassociation of interleukin-1 receptor antagonist genotypes with bone mineral density, bone turnover status, and estrogen responsiveness in Korean postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Relations between interleukin-1, its receptor antagonist gene polymorphism, and bone mineral density in postmenopausal Korean women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Pathological role of osteoclast costimulation in arthritis-induced bone loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

CTLA-4 directly inhibits osteoclast formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1462-4

Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage

21 January 2018

1 reference

12 December 2020

Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products

1 reference

12 December 2020

Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study

1 reference

12 December 2020

Bone mineral mass is associated with interleukin 1 receptor autoantigen and TNF-alpha gene polymorphisms in post-menopausal Mediterranean women

1 reference

12 December 2020

Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers

1 reference

12 December 2020

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

12 December 2020

Osteopenia in adults with a history of juvenile rheumatoid arthritis. A population based study

1 reference

12 December 2020

Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis

1 reference

12 December 2020

Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment

1 reference

12 December 2020

Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis

1 reference

12 December 2020

Generalised bone loss in patients with early rheumatoid arthritis

1 reference

12 December 2020

Clinical associations of dual-energy X-ray absorptiometry measurement of hand bone mass in rheumatoid arthritis

1 reference

12 December 2020

New radiographic bone erosions in the wrists of patients with rheumatoid arthritis are detectable with magnetic resonance imaging a median of two years earlier

1 reference

12 December 2020

Interleukin-1 lymphocyte chemotactic activity in rheumatoid arthritis synovial fluid

1 reference

12 December 2020

Osteoporosis in early ankylosing spondylitis: a primary pathological event?

1 reference

12 December 2020

TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis

1 reference

12 December 2020

Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy

1 reference

12 December 2020

Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis

1 reference

12 December 2020

Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression

1 reference

12 December 2020

The effect of natural and surgical menopause on the secretion of cytokines from human blood monocytes

1 reference

12 December 2020

Production of interleukin 1 in the joint during the development of antigen-induced arthritis in the rabbit

1 reference

12 December 2020

Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides

1 reference

12 December 2020

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial

1 reference

12 December 2020

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

1 reference

12 December 2020

Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study

1 reference

12 December 2020

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

1 reference

12 December 2020

Dickkopf-1 is a master regulator of joint remodeling

1 reference

12 December 2020

Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis

1 reference

12 December 2020

Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis

1 reference

12 December 2020

Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women

1 reference

12 December 2020

What is the fate of erosions in early rheumatoid arthritis? Tracking individual lesions using x rays and magnetic resonance imaging over the first two years of disease

1 reference

12 December 2020

Lack of association between interleukin-1 receptor antagonist protein gene polymorphism and bone mineral density in Hungarian postmenopausal women

1 reference

12 December 2020

Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab

1 reference

12 December 2020

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

10.1007/S00198-010-1462-4

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20959960